Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Zevra Therapeutics, Inc. on May 29, 2025. The meeting addressed the election of Class I directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Of the 54,679,363 shares outstanding as of the April 4, 2025 record date, 81.4% (44,517,743 shares) were present or represented by proxy. The following matters were voted upon:
- Election of Directors: Wendy Dixon, Ph.D., and Tamara A. Favorito were elected as Class I directors.
- Contested Nomination: Stockholder Daniel J. Mangless nominated Travis C. Mickle, Ph.D., and Arthur C. Regan. These nominations were disregarded because Mr. Mangless failed to comply with Rule 14a-19(a)(3) regarding solicitation thresholds and failed to provide evidence of compliance by the May 19, 2025 deadline. He also did not attend the meeting to validly nominate them.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Tabulation Summary
| Proposal / Nominee | For | Withheld / Against | Broker Non-Votes |
|---|---|---|---|
| Wendy Dixon, Ph.D. | 25,795,548 | 9,075,888 | 9,645,307 |
| Tamara A. Favorito | 25,599,993 | 9,272,443 | 9,645,307 |
| Travis C. Mickle, Ph.D. (Disregarded) | 9,221,892 | 25,649,775 | 9,646,076 |
| Arthur C. Regan (Disregarded) | 8,359,291 | 26,512,375 | 9,646,077 |
| Ratification of Ernst & Young LLP | 43,775,884 | 360,221 | 0 |
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding financial performance or operational strategy. The primary risk disclosed relates to the contested director election, which was resolved in favor of the company's board nominees due to the dissident stockholder's procedural non-compliance.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following the election of Dr. Dixon and Ms. Favorito.
- Confirm the status of the relationship with stockholder Daniel J. Mangless and any potential future governance disputes.
- Review the definitive proxy statement filed on April 21, 2025, for detailed biographical information on the elected directors.
- Check subsequent filings for the company's financial results, as this 8-K contains no financial data.